IL1RL2 and psoriasis vulgaris: To clarify, if inhibition of IL-36 signaling can block IL-17A-driven plaque psoriasis, especially when inflammation has already been induced, we investigated the effects of systemic anti-IL36R antibody application in two different mouse models.